Trastuzumab: unusual responses and toxicities.
Trastuzumab has become the standard of care in the management of human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancers, both in the metastatic and adjuvant setting. Emerging data show continued efficacy of the drug even after disease progression in combination with chemotherapy. While cardiotoxicity is well recognized with trastuzumab, unusual pulmonary toxicities are becoming apparent. Cases that reflect the unusual efficacy and unusual toxicity of trastuzumab are reported.
Ahamed
Eliyaz
E
Department of Medical Oncology, First floor, Charing Cross Hospital, Fulham Palace Road, London, UK. e.ahamed@imperial.ac.uk
Mauri
Francesco A
FA
Pakter
Grant
G
Lim
Adrian
A
Stebbing
Justin
J
D000911:Antibodies, Monoclonal / Q000633:toxicity*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols; D001943:Breast Neoplasms / Q000503:physiopathology / Q000628:therapy*; D005260:Female; D006801:Humans; D008168:Lung / Q000187:drug effects*; D008875:Middle Aged; D017239:Paclitaxel / Q000494:pharmacology; D011014:Pneumonia / Q000139:chemically induced; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D000068878:Trastuzumab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D017239:Paclitaxel; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human